Xiaozhi Pills On Clinical Observation On Non-alcoholic Fattyliver

Objective Evaluation Cellulite pill treatment of nonalcoholic fatty liver efficacy andsafety.Methods The topics to40patients with nonalcoholic fatty liver disease from HenanInstitute of Chinese Medicine inpatient and outpatient gallbladder and stomach is observedobject, randomized, double-blind, placebo-controlled approach to the drug for the treatmentof Cellulite Pills of patients met the inclusion criteria, in accordance with the order oftreatment, were randomly divided into two groups (treatment group and the control group),20patients in each. Clinically, liver and spleen CT ratio, lipids, body mass index (BMI) andTCM syndrome score as the outcome measures, and data analysis.Results1.the two groups after treatment, the symptoms score were significantly lower thanbefore treatment (P <0.01), and the treatment group score improved significantly. Thetreatment group than the control group can obviously reduce threats rib pain, oftenabdominal distension full, god clinical symptoms such as fatigue (P <0.01).2, liver and spleen CT ratio test results before and after treatment showed that the treatmentgroup and the control group were elevated liver and spleen CT ratio, the treatment groupcompared with the control group there was a significant difference (P <0.01).3.the two groups after treatment the blood fat, body mass index (BMI) were improved, andhas significance (P <0.01); The treatment group compared with control group aftertreatment, blood lipids decreased but no significance (P>0.05).Conclusions1. disappear fat pill treatment of nonalcoholic fatty liver disease, safe andeffective.2.disappear fat pill can obviously reduce pain of patients with nonalcoholic fatty liverdisease, a rib, god often abdominal distension full, clinical symptoms such as fatigue,clinical curative effect is superior to the control group.3.disappear fat pill can be elevated in patients with nonalcoholic fatty liver disease of liverand spleen CT ratio, body mass index (BMI), promote patients with nonalcoholic fatty liverdisease rehabilitation.